^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CHM 1101

    i
    Other names: CHM 1101, CLTX-CAR T cell therapy, Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, CHM1101, CHM-1101
    Associations

    News

    Trials
    Company:
    Chimeric Therap, City of Hope
    Drug class:
    CLTX-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    4ms
    Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety. (PubMed, Cell Rep Med)
    Here, we report interim clinical experience of a phase 1 trial evaluating intracavity/intratumoral (ICT) delivery of CLTX-CAR T cells in four patients with MMP-2-expressing recurrent GBM (NCT04214392), with the primary objectives of feasibility and safety...Human anti-CAR antibody assays do not detect humoral immunogenicity against the CLTX-CAR. These observations support further clinical evaluation of CLTX-CAR therapy.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    6ms
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=36 --> 19
    Enrollment closed • Enrollment change
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    1year
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial primary completion date: Sep 2024 --> Aug 2025
    Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    over1year
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Chimeric Therapeutics | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Oct 2025
    Enrollment closed • Trial primary completion date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    over1year
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2026 --> Sep 2025 | Trial primary completion date: Aug 2026 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    almost2years
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    almost2years
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Chimeric Therapeutics
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    2years
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Chimeric Therapeutics | Phase classification: P1b --> P1
    Phase classification • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    2years
    Initial clinical experience with chlorotoxin-redirected CAR T cells for patients with recurrent glioblastoma (SITC 2023)
    Results Here we report clinical outcomes and correlative observations for four lead-in research participants, all of whom had a histopathological diagnosis of glioblastoma, idh wild type, grade 4, and who had received prior temozolomide as well as radiation and other treatments. Conclusions Phase 1 clinical observations to date confirm the feasibility and safety of CLTX-CAR T cell immunotherapy for patients with GBM. These studies will lead to determination of a maximum tolerated dose/maximum feasible dose.
    Clinical • Late-breaking abstract • CAR T-Cell Therapy • IO biomarker
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    temozolomide • CHM 1101
    over2years
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1b, N=42, Recruiting, Chimeric Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    over2years
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101